RxDoctor Payments Data

Derek Gallucci, DO

Family Medicine · Williamsville, NYNPI 1346508991

Payments from drug & device makers

$829in general payments, 2019–2025

Across 59 payments — averaging $14.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$193
  • GSK$147
  • Okami Medical, Inc.$120
  • Boehringer Ingelheim$110
  • Dexcom, Inc.$56
  • Phathom Pharmaceuticals, Inc.$51
  • plus $152 from 7 others

What the payments were for

  • Food & beverage$829100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$829 in reported general payments places this provider in the 60th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$31,916
Medicare patients
139
Services billed
402

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide137$156,301
JardianceEmpagliflozin77$89,629
EliquisApixaban62$51,599
TrulicityDulaglutide39$35,401
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$24,954
MounjaroTirzepatide23$24,171
XareltoRivaroxaban21$15,944
FarxigaDapagliflozin Propanediol15$11,364
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog14$8,603
Fluticasone-SalmeterolFluticasone Propion/Salmeterol64$8,462
Rosuvastatin Calcium356$5,728
Atorvastatin Calcium324$5,247
Novolog FlexpenInsulin Aspart16$4,925
Metformin Hcl ErMetformin Hcl204$4,438
Duloxetine Hcl123$3,845

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$193$156,301137 claims
Boehringer IngelheimJardiance$110$89,62977 claims
Lilly USA, LLCTrulicity, Mounjaro$15$59,57262 claims
PfizerEliquis$14$51,59962 claims
GSKTrelegy Ellipta$147$24,95429 claims
AstraZenecaFarxiga$31$11,36415 claims
AbbVieSynthroid$42$2,12127 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 4,321 family medicine providers in New York.

Other family medicine in Williamsville

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →